Trifunctional Antibodies


    This website is to provide medical trade journalists with information on the most important study results as well as background information on the development of trifunctional antibodies.

    For questions or further details, please contact Dr. Bernd Ebeling: bernd.ebeling@fresenius.com, Tel: +49 (0) 6172-608-2378.


    • Video interview with a lead investigator

    • Animated video on trifunctional antibodies

    • Background information

    • Pictures and illustrations

    • Further material


    Video interview with a lead investigator

    Simon Parsons (Nottingham/UK), leading expert involved in the development of trifunctional antibodies, answers questions on the investigation of catumaxomab in patients with malignant ascites. Click the questions to get answers:
    • What is malignant ascites?
      (0:47 min., wmv file, 1.6 MB)
    • What are the symptoms?
      (0:39 min., wmv file, 1.3 MB)
    • What are the diagnostic options?
      (0:46 min., wmv file, 1.5 MB)
    • What are the current therapeutic options?
      (1:01 min., wmv file, 2.1 MB)
    • What could be the advantage of a therapy with trifunctional antibodies?
      (0:31 min., wmv file, 1.1 MB)
    • What could be the benefit of the trifunctionality?
      (0:28 min., wmv file, 975 KB)
    • Which patients could benefit from a therapy with trifunctional antibodies?
      (0:36 min., wmv file, 1.4 MB)

    Watch the full interview here (5:05 min., wmv file, 11 MB)


    Animated video on trifunctional antibodies

    This video animation visualizes and explains the mode of action of trifunctional antibodies:
    • Video Triomab® (2:53 min.)

       (wmv file, high quality, 10 MB)

       (wmv file, low quality, 4 MB)


    Background information

    Fact sheets describing the development of trifunctional antibodies and the proposed areas of application:

    • Trifunctional antibodies
       pdf file (39 KB)
    • Clinical studies with trifunctional antibodies
       pdf file (31 KB)
    • Malignant ascites
       pdf file (40 KB)
    • Breast cancer
       pdf file (22 KB)
    • Ovarian cancer
       pdf file (21 KB)
    • Gastric cancer
       pdf file (21 KB)



    Pictures and illustrations

    Provided that the source is named, these photos and illustrations may be used free of charge in independent media such as newspapers and magazines as well as for web pages run by these media. Fresenius Biotech must give its expressed approval for the photos and illustrations to be used for any other purpose.

    • The postulated tri-cell-complex
      JPEG download in resolution: 2362 x 1670 (684 KB)
    • Trifunctional antibody for targeted cancer therapy
      JPEG download in resolution: 1292 x 1599 (311 KB)
    • Pathophysiology of malignant ascites
      JPEG download in resolution: 2516 x 1612 (231 KB)
    • Tumour cells in an ascites aspirate surrounded by immune cells
      Picture 1 - JPEG download in resolution: 643 x 484 (237 KB)
      Picture 2 - JPEG download in resolution: 643 x 484 (240 KB)


    Further material

    • Company profile
       pdf file (123 KB)




    © 03.06.2007 Fresenius SE